# DESCRIPTION

## BACKGROUND

- motivate influenza vaccines

## SUMMARY

- introduce mosaic influenza antigenic polypeptides
- describe engineered HA polypeptides
- outline method of engineering mosaic HA polypeptide
- describe selecting sequences for epitopes and antigenic regions
- outline method of engineering mosaic NA polypeptide
- describe selecting sequences for epitopes and antigenic regions
- describe obtaining HA amino acid sequences
- describe obtaining NA amino acid sequences
- provide engineered mosaic influenza HA or NA polypeptide

## DEFINITIONS

- define terms used in the specification
- introduce singular and plural forms of terms
- define adjuvant
- define administer
- define affinity
- define animal
- define antibody
- define antigen
- define approximately
- define associated with
- define binding
- define host cell
- define immune response
- define immunogen
- define in vitro and in vivo
- define influenza virus and vaccine
- define isolated and nucleic acid
- define pandemic strain and other terms
- define recombinant
- define recombinant influenza vaccine
- define reference
- define specificity
- define various terms

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

- define scope of invention

### Engineering Mosaic Influenza Antigens

- motivate influenza vaccine development
- describe limitations of current vaccines
- introduce SMARt methodology
- describe engineering of mosaic epitope sequences
- outline steps of SMARt methodology
- describe benefits of engineered HA polypeptides
- discuss various techniques for obtaining and aligning influenza sequences
- describe visualization of principal components
- outline modifications to engineered HAs or NAs

### Exemplary Mosaic Sequence Patterns and Engineered HA Polypeptides

- define receptor-binding site (RBS)
- describe epitopes or antigenic regions
- specify mosaic sequence patterns for RBS
- provide examples of mosaic sequence patterns
- list residues for mosaic sequence patterns
- define mosaic sequence patterns
- describe engineered HA polypeptides
- provide exemplary templates and backbone sequences
- refine mosaic antigens by molecular modeling

### Nucleic Acid Construction and Expression

- construct and express nucleic acid molecules

### Conformation of Engineered HA or NA Polypeptides

- assess and select engineered HA or NA polypeptides

### Pharmaceutical Compositions

- define engineered HA or NA polypeptides
- describe pharmaceutical compositions including engineered HA or NA polypeptides
- formulate immunogenic compositions, e.g., vaccines
- provide methods of preventing or treating influenza infections
- administer pharmaceutical compositions to subjects
- test subjects for antibodies to engineered HA or NA polypeptides
- select dose and regimen for administration
- use reverse genetics methods to produce infectious reassortant influenza viruses
- describe various cell substrates for growing influenza virus or producing engineered hemagglutinin polypeptides
- formulate therapeutic compositions, including influenza VLPs, fusion proteins, and engineered HA polypeptides

## EXAMPLES

- describe design and methodology for construction of hemagglutinin polypeptides

### Example 1. Design and Methodology for Construction of Hemagglutinin (HA) Polypeptides

- motivate engineered HA polypeptides for broad neutralizing immune responses
- describe principal component analysis to assess cross reactivity of influenza B HAs
- outline structural mapping of antigenic repertoires (SMARt) workflow
- describe structural modeling and selection of designs

### Example 2. Structural Mapping of Antigenic Repertoires (SMARt) Workflow

- describe SMARt approach for creating broadly protective HA-based vaccine
- outline epitope sequence pattern selection and optimization
- describe create multiple sequence alignment
- identify epitopes for target protein of interest
- describe antigenic repertoires identification
- outline cassette subsets of unique epitope sequence patterns

### CONCLUSIONS

- summarize SMARt approach for generating broadly protective vaccines

### Example 3. In Vivo Efficacy of Engineered Mosaic Influenza A HA and NA Polypeptides

- prepare VLPs containing engineered mosaic hemagglutinins
- assess immunogenicity of engineered mosaic HA designs

### Example 4. In Vivo Efficacy of Engineered Mosaic Influenza B HA Polypeptides

- immunize mice with rHAs and evaluate immunogenicity

## EQUIVALENTS

- define claim interpretation rules

